On this page you will find links to key resources and tools to enable robust vaccine trial design during the COVID-19 outbreak, as well as the latest information regarding ongoing vaccine trials and potential COVID-19 vaccines.
Are you considering conducting a vaccine trial? If so, then please let us know what you have planned and if you need any support. Are you looking for groups to collaborate with? Do you want to let others know that you would like to collaborate with another group?
We want to support any team wanting to run a high-quality COVID-19 trial in different settings, and especially in LMICs. We can help coordinate discussions and support your plans. We can also set up a forum for developing ideas and asking questions. Please get in touch and get involved!
Latest news and resources on COVID-19 Vaccine
COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global roll-out
COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week
Final first round of allocations for doses of AstraZeneca/Oxford and Pfizer-BioNTech vaccines, to the majority of countries and economies participating in the COVAX Facility, anticipated to be published in the coming days
Beginning of global rollout means that, as readiness criteria are met and doses produced, vaccines will be shipped to Facility participants on a rolling basis
Countries should tithe their vaccines by Gavin Yamey in Nature
Although around 190 nations have joined COVAX, about 3 dozen rich nations ended up buying most of their doses by way of direct deals with vaccine companies rather than through the COVAX pool. COVAX still expects to secure some 2 billion doses by the end of 2021, but richer countries have already bought 5.8 billion doses, often purchased before clinical trials were completed, through bilateral deals. COVAX is still getting pushed to the back of the queue. What to do now?
FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 (February 26, 2021)
The COVID-19 candidate vaccine landscape database compiles detailed information on COVID-19 vaccine candidates in development. The landscape is updated regularly - twice a week (Tuesday and Friday, 17:00 CET).
COVID-19 vaccination training for health workers provides information that health workers need to know to conduct COVID-19 vaccinatio
Orientation to national deployment and vaccination planning for COVID-19 vaccines provides orientation for national deployment and vaccination planning for COVID-19 vaccines
USE THE LINKS BELOW TO NAVIGATE VACCINES:
What support is available?
The European Medicines Agency (EMA) encourages developers of potential vaccines or treatments for novel coronavirus infection to contact EMA as soon as possible to discuss their strategy for evidence-generation, by emailing email@example.com. The EMA can also provide medicine developers with scientific advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks. Scientific advice is free of charge and can be fast-tracked for potential novel coronavirus treatments or vaccines.
In response to the emergence of COVID-19, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) has developed a portfolio of resources to accelerate outbreak research and response.
Fundação Oswaldo Cruz (Fiocruz) has created a resource area highlighting important sources of information about the pandemic, to facilitate the circulation of knowledge and help the entire scientific community to keep abreast of the latest news about the disease.